PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRemetinostat
Remetinostat
Remetinostat is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
10% methyl salicylate pain relief patchC2002632024-06-27
1st medxpatchC2002632024-10-31
365 whole foods market anticavity/antigingivitis mouthwashOTC monograph not final2022-05-12
701 dieda zhengtong yaogao medicatedOTC monograph not final2019-11-13
701 dieda zhengtong yaogao medicated plasterOTC monograph not final2014-06-26
advanced antiseptic citrusC2002632025-02-20
advanced citrus antisepticC2002632025-01-10
advil targeted reliefC2002632024-02-08
ageless pain reliefC2002632023-12-12
air sinsin pasOTC monograph final2011-06-06
Show 682 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
666 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11123
Diabetes mellitusD003920EFO_0000400E08-E1322
Liver diseasesD008107EFO_0001421K70-K7711
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8111
Fatty liverD005234EFO_000393411
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic nephropathiesD003928EFO_000040111
Kidney diseasesD007674EFO_0003086N0811
Liver cirrhosisD008103EFO_0001422K74.011
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients22
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRemetinostat
INNremetinostat
Description
Remetinostat is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Classification
Small molecule
Drug classenzyme inhibitors: histone deacetylase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL3707219
ChEBI ID
PubChem CID
DrugBank
UNII ID37NT056AT4 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 27 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aptensio xr, Concerta, Cotempla xr-odt, Covaryx, Covaryx covaryx, Daytrana, Diclovix, Diclovix m, Dyural 40 kit, Dyural 80 kit, Dyural 80-lm, Dyural lm kit, Eemt, Eemt eemt, Esterified estrogens and methyltestosterone, Estratest f.s., Estratest f.s. estratest h.s., Fenovar, Healthy mamabe well rounded, Hycodan, Hydrocodone bitartrate and homatropine methylbromide, Hydromet, Jornay pm, Metadate cd, Metadate er, Methylene blue, Methylene blue inj, Methylin, Methylphenidate, Methylphenidate hydrochloride, Methylphenidate hydrochloride (la), Methylphenidate hydrochloride extended release, Methylphenidate transdermal system, Perseris, Physicians ez use m-pred, Prenate elite, Prenate essential, Provayblue, Quillichew er, Quillivant, Relexxii, Ritalin, Varophen
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use